• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.

作者信息

Chen Zhiwei, Wang Xiaodong, Ye Shuang

机构信息

Renji Hospital South Campus, Shanghai, China

出版信息

N Engl J Med. 2019 Jul 18;381(3):291-293. doi: 10.1056/NEJMc1900045.

DOI:10.1056/NEJMc1900045
PMID:31314977
Abstract
摘要

相似文献

1
Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.托法替布治疗无肌病性皮肌炎相关间质性肺疾病
N Engl J Med. 2019 Jul 18;381(3):291-293. doi: 10.1056/NEJMc1900045.
2
Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.托法替布治疗抗黑色素瘤分化相关 5 基因抗体阳性皮肌炎的难治性间质性肺病。
Rheumatology (Oxford). 2018 Dec 1;57(12):2114-2119. doi: 10.1093/rheumatology/key188.
3
Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.抗MDA5抗体阳性的临床无肌病性皮肌炎合并快速进展性间质性肺病，通过启动联合免疫抑制治疗加血浆置换，随后将他克莫司换为托法替布成功治疗。
Intern Med. 2024 Sep 15;63(18):2571-2578. doi: 10.2169/internalmedicine.2915-23. Epub 2024 Feb 12.
4
Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies.成功地增加托法替尼剂量治疗抗黑色素瘤分化相关基因 5 抗体相关的难治性皮肌炎和间质性肺病。
Mod Rheumatol Case Rep. 2021 Jan;5(1):76-81. doi: 10.1080/24725625.2020.1816674. Epub 2020 Sep 14.
5
Rapidly progressive interstitial lung disease in a patient with anti-MDA5-positive amyopathic dermatomyositis.抗MDA5阳性无肌病性皮肌炎患者的快速进展性间质性肺疾病
Scand J Rheumatol. 2018 Jul;47(4):334-335. doi: 10.1080/03009742.2017.1369155. Epub 2017 Oct 18.
6
Efficiency of tofacitinib in refractory interstitial lung disease among anti-MDA5 positive juvenile dermatomyositis patients.托法替布在抗MDA5阳性幼年皮肌炎患者难治性间质性肺疾病中的疗效
Ann Rheum Dis. 2023 Nov;82(11):1499-1501. doi: 10.1136/ard-2023-223919. Epub 2023 Jun 6.
7
Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis.托法替布治疗抗MDA5抗体阳性皮肌炎患者缓慢进展性间质性肺病的疗效
Clin Immunol. 2020 Jun;215:108451. doi: 10.1016/j.clim.2020.108451. Epub 2020 Apr 29.
8
Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.托法替布联合多学科治疗成功治愈抗MDA5抗体阳性皮肌炎患者的难治性间质性肺病和气纵膈
J Clin Rheumatol. 2021 Dec 1;27(8S):S574-S577. doi: 10.1097/RHU.0000000000000984.
9
Management of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report.抗黑色素瘤分化相关基因 5 抗体诱导的难治性皮肌炎并发间质性肺病采用托法替布治疗及其结局：一例报告。
J Med Case Rep. 2024 Sep 28;18(1):471. doi: 10.1186/s13256-024-04793-9.
10
Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.托法替布用于抗黑色素瘤分化相关基因5抗体阳性临床无肌病性皮肌炎缓解后复发：一例报告
Medicine (Baltimore). 2020 Sep 11;99(37):e21943. doi: 10.1097/MD.0000000000021943.

引用本文的文献

1
Characteristics and Outcomes of Diffuse Interstitial Pneumonias Discovered in the ICU: A Retrospective Monocentric Study-The "IPIC" (Interstitial Pneumonia in Intensive Care) Study.重症监护病房中发现的弥漫性间质性肺炎的特征与转归：一项回顾性单中心研究——“IPIC”（重症监护中的间质性肺炎）研究
Diagnostics (Basel). 2025 Aug 9;15(16):1995. doi: 10.3390/diagnostics15161995.
2
A pilot transcriptomic study of a novel multitargeted BRT regimen for anti-MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy.一项针对抗MDA5抗体阳性皮肌炎的新型多靶点BRT方案的初步转录组学研究：与传统疗法相比提高生存率。
Front Immunol. 2025 Aug 7;16:1568338. doi: 10.3389/fimmu.2025.1568338. eCollection 2025.
3
Severe laryngeal oedema unexpectedly observed during bronchoscopy in a patient with anti-MDA5-positive dermatomyositis.
一名抗MDA5阳性皮肌炎患者在支气管镜检查期间意外出现严重喉水肿。
BMJ Case Rep. 2025 Aug 11;18(8):e266696. doi: 10.1136/bcr-2025-266696.
4
Dermatomyositis: focus on cutaneous features, etiopathogenetic mechanisms and their implications for treatment.皮肌炎：关注皮肤特征、发病机制及其对治疗的意义。
Semin Immunopathol. 2025 Aug 6;47(1):32. doi: 10.1007/s00281-025-01054-9.
5
Dazukibart for dermatomyositis: expanding the therapeutic arsenal.用于皮肌炎的大冢奇方：扩充治疗手段
Ann Transl Med. 2025 Jun 27;13(3):24. doi: 10.21037/atm-25-44. Epub 2025 Jun 24.
6
Anti-interferon-α antibodies associate with disease activity and prognosis in anti-MDA5-positive dermatomyositis.抗干扰素-α抗体与抗MDA5阳性皮肌炎的疾病活动度及预后相关。
Arthritis Res Ther. 2025 Jul 2;27(1):133. doi: 10.1186/s13075-025-03600-0.
7
Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease.与结缔组织病相关的间质性肺病中进行性纤维化表型的预测生物标志物和新疗法
Biomedicines. 2025 Jun 13;13(6):1463. doi: 10.3390/biomedicines13061463.
8
Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease.Janus激酶抑制剂在炎症性肠病纤维化管理中的治疗潜力。
J Crohns Colitis. 2025 Jun 4;19(6). doi: 10.1093/ecco-jcc/jjaf087.
9
JAK-STAT Signaling in Autoimmunity and Cancer.自身免疫与癌症中的JAK-STAT信号传导
Immunotargets Ther. 2025 May 11;14:523-554. doi: 10.2147/ITT.S485670. eCollection 2025.
10
Anti- Melanoma Differentiation-Associated Gene 5 Antibody Positive Dermatomyositis: Recent Progress in Pathophysiology and Treatment.抗黑色素瘤分化相关基因5抗体阳性皮肌炎：病理生理学与治疗的最新进展
Curr Rheumatol Rep. 2025 May 5;27(1):23. doi: 10.1007/s11926-025-01188-7.